Market Newsdesk

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA in the Photronics Securities Class Action Where Shareholders Lost $19.49 Per Share

NEW YORK, Aug. 12, 2026 /PRNewswire/ — IMPORTANT DATE: September 4, 2026. Investors who wish to seek appointment as lead plaintiff in the Photronics, Inc. (NASDAQ: PLAB) securities class action must file a motion by this date. Start your claim now before the deadline or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

PLAB shares fell $19.49 per share, a decline of 36.42%, on May 28, 2026. The class period runs from December 10, 2025 through May 27, 2026.

What is a Lead Plaintiff?

Under the Private Securities Litigation Reform Act of 1995, the court appoints a lead plaintiff to represent all class members. The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case. Any investor who purchased PLAB securities during the class period and suffered losses may apply.

Lead Plaintiff Facts

• The lead plaintiff selects and directs lead counsel for the entire class
• Courts generally presume the applicant with the largest provable loss is the most adequate plaintiff
• There is no minimum loss threshold required to apply
• In the Photronics case, lead plaintiff applicants must demonstrate losses from purchases between December 10, 2025 and May 27, 2026
• Serving as lead plaintiff involves no out-of-pocket cost
• Multiple investors may join together as a lead plaintiff group

Absent Class Member Rights

Investors who do not seek lead plaintiff appointment remain absent class members. Absent class members are not required to take any action before September 4, 2026 and retain the right to participate in any recovery obtained on behalf of the class. No investor is excluded from the case for choosing not to apply as lead plaintiff.

Post-Deadline Procedures

After the September 4, 2026 deadline passes, the court will review all motions and appoint the lead plaintiff. The appointed lead plaintiff will then select lead counsel. Discovery, briefing, and settlement negotiations follow. Most class members never appear in court or provide testimony.

“The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests in the outcome. In the Photronics action, investors who purchased during the class period and experienced the $19.49 per-share decline should evaluate whether lead plaintiff appointment aligns with their interests.” — Joseph E. Levi, Esq.

Find out if you qualify to recover losses or call Joseph E. Levi, Esq. at (212) 363-7500.

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years. Investors who suffered losses have until September 4, 2026 to seek appointment as lead plaintiff. Attorney Advertising. Prior results do not guarantee similar outcomes.

Frequently Asked Questions About the PLAB Lawsuit

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: How do I know if I lost enough money to be the lead plaintiff? A: There is no minimum loss threshold. Courts appoint the investor with the largest provable loss who is willing and able to represent the class adequately. Contact Levi & Korsinsky before September 4, 2026 to evaluate.

Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I already sold my PLAB shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/plab-shareholder-alert-photronics-inc-securities-class-action-lawsuit—investors-with-losses-may-contact-levi–korsinsky-302849583.html

SOURCE Levi & Korsinsky, LLP

Market Reaction Focus: Alibaba ADSs repriced across three separate trading sessions in June 2026 as a U.S. Department of Defense designation and allegations of unauthorized AI “distillation” reached the market, in a period the complaint alleges followed materially misleading disclosures.

NEW YORK, Aug. 12, 2026 /PRNewswire/ — Levi & Korsinsky, LLP alerts investors in Alibaba Group Holding Limited (NYSE: BABA) that a securities class action is pending on behalf of purchasers of Alibaba securities between June 26, 2025 and June 24, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

BABA ADSs fell $4.69 (approximately 3.9%) over two sessions to close at $115.38, then $2.80 (2.7%) to $99.80, then $4.73 (4.7%) to $95.07, a cumulative decline of roughly 45% from the Class Period high of $173.68 recorded on October 9, 2025. Investors have until October 5, 2026 to seek lead plaintiff status.

How the Market Repriced BABA in June 2026

After the close on June 8, 2026, the U.S. Department of Defense published an updated list of Chinese military companies that included Alibaba, based on affiliation with the Chinese Ministry of Industry and Information Technology. The pleading asserts that the Company’s prior risk disclosures identified other Chinese issuers affected by U.S. restrictions while omitting that Alibaba itself met the statutory definition under the FY2025 NDAA.

Shortly before the close on June 24, 2026, Bloomberg reported that Anthropic PBC accused Alibaba of illicitly accessing its Claude AI model. Selling pressure carried into the following session.

Trading Impact by the Numbers

• Class Period high: $173.68 per ADS on October 9, 2025
• June 8, 2026 designation: $4.69 decline (approximately 3.9%) to $115.38 by June 10, 2026
• June 24, 2026 Bloomberg report: $2.80 decline (2.7%) to $99.80
• June 25, 2026 follow-through: $4.73 decline (4.7%) to $95.07
• Cumulative decline from the Class Period high: approximately $78.61 per ADS, or about 45%
• Reported scope of the alleged campaign: 28.8 million exchanges and roughly 25,000 fraudulent accounts

What the Complaint Charges About the Disclosures

As averred in the action, annual report language describing “unauthorized distillation of third-party models” as a perceived or alleged risk was misleading because the practice was allegedly already underway. The complaint charges that Alibaba securities traded at artificially inflated prices until these matters reached the market.

“Corporate officers have a duty to ensure their companies’ public statements are accurate and complete. Here, the complaint alleges that Alibaba’s filings flagged U.S. restrictions on Chinese military companies without disclosing that Alibaba itself allegedly fell within that classification.” — Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the BABA Lawsuit

Q: How much did BABA stock drop? A: Shares declined across three sessions in June 2026, closing at $95.07 on June 25, 2026, approximately 45% below the Class Period high of $173.68. Investors who purchased during the Class Period at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: When did Alibaba allegedly mislead investors? A: The Class Period runs from June 26, 2025 to June 24, 2026. The complaint alleges that corrective disclosures, including the Department of Defense designation and the Anthropic allegations, revealed information that caused significant declines.

Q: What court was the BABA class action filed in? A: The case was filed in the United States District Court for the Southern District of New York, governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class, typically the investor with the largest documented losses. Appointment does not increase individual recovery but provides direct oversight of the litigation.

Q: What do BABA investors need to do right now? A: Gather brokerage records showing purchase dates, share quantities, and prices paid, then contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.

Q: What if I already sold my BABA shares? A: Eligibility is based on when you purchased, not whether you still hold the ADSs. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges, including NYSE-listed ADSs, regardless of the investor’s country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-alibaba-group-holding-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-5-2026—baba-302849611.html

SOURCE Levi & Korsinsky, LLP

Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune’s RP1 disclosures omitted unresolved FDA study-design concerns.

NEW YORK, Aug. 12, 2026 /PRNewswire/ — Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action brought on behalf of shareholders who purchased securities between October 20, 2025 and April 10, 2026. Find out if you may be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

REPL shares closed at a Class Period high of $10.73 on December 8, 2025 and closed at $1.70 on April 13, 2026, a cumulative decline of $9.03 per share, or approximately 84.16%. The window to apply for lead plaintiff closes on October 5, 2026.

The Named Individual Defendants

The securities action names Sushil Patel, Ph.D., Chief Executive Officer at all relevant times, and Emily Hill, Chief Financial Officer at all relevant times, alongside the Company. As claimed, both officers held the power and authority to control the contents of Replimune’s SEC reports, press releases, and presentations to analysts and institutional investors during the Class Period.

Alleged Control Person Liability

The securities action asserts claims under Section 20(a) of the Securities Exchange Act of 1934 in addition to Section 10(b) and Rule 10b-5. As claimed:

• Both officers allegedly received copies of the reports and press releases at issue prior to or shortly after issuance and had the ability to prevent or correct them.
• Each certified periodic filings under the Sarbanes-Oxley Act, including Sections 302 and 906, for the quarters ended September 30, 2025 and December 31, 2025.
• The complaint alleges those filings omitted that previously communicated FDA study-design concerns regarding the RPL-001-16 (IGNYTE) single-arm trial had not been addressed.
• The complaint further alleges the officers did not disclose that the resubmission relied on an early unplanned analysis from RP1-104 covering only 40 patients, or 10% of planned enrollment.
• Section 20(a) may impose liability on controlling persons for the alleged primary violations of the entity they controlled.

“Corporate officers have a duty to ensure their companies’ public statements are accurate and complete. Here, the complaint alleges that senior officers certified filings describing the RP1 resubmission as a complete response to the FDA while study-design concerns the agency had communicated remained unresolved.” — Joseph E. Levi, Esq.

Scienter Allegations Against the Officers

Because of their positions and access to material non-public information, the individual defendants allegedly knew that the adverse facts had not been disclosed and that the Company’s positive representations were then materially misleading. The action seeks to recover damages for purchasers who acquired REPL securities at allegedly inflated prices.

Submit your information to learn more or call (212) 363-7500.

Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the REPL Lawsuit

Q: Who are the defendants named in the REPL lawsuit? A: The complaint names Replimune Group, Inc. and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.

Q: What specific misstatements does the REPL lawsuit allege? A: The complaint alleges Replimune Group, Inc. made materially false or misleading statements regarding the status of its RP1 biologics license resubmission, including that previously communicated FDA study-design concerns had been addressed and that the resubmission was a complete response to the July 2025 complete response letter, during the Class Period. When the FDA’s rejection of the BLA was disclosed, the stock price declined sharply.

Q: What court was the REPL class action filed in? A: The case was filed in the United States District Court for the District of Massachusetts, governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my REPL shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-replimune-group-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-5-2026—repl-302849600.html

SOURCE Levi & Korsinsky, LLP

Capricor Therapeutics shares collapsed from $19.70 to $4.19 following FDA briefing documents and an adverse advisory committee vote, falling an aggregate 15.08 per share across two corrective-disclosures, or 78.7%, according to allegations in a pending securities class action.

NEW YORK, Aug. 12, 2026 /PRNewswire/ — Levi & Korsinsky, LLP alerts investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) that a securities class action has been filed on behalf of shareholders who purchased securities between December 17, 2025 and July 26, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

CAPR closed at $7.00 on July 27, 2026, down $12.70 or 64% in a single session on unusually heavy volume. Shares fell another $2.38, or 36%, to $4.19 on July 30, 2026. Measured against the Class Period high of $35.34 on April 21, 2026, the decline through July 30, 2026 exceeded $31 per share. Investors have until September 28, 2026 to seek lead plaintiff status.

The Two Trading Sessions That Repriced CAPR

On the morning of July 27, 2026, FDA released briefing documents ahead of its advisory committee meeting on the deramiocel Biologics License Application. The documents stated that the HOPE-3 study “did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months,” and that “the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness.” The lawsuit contends this disclosure corrected prior alleged misstatements about the trial’s results.

Two sessions later, following the July 29 advisory committee meeting, Medscape reported that the panel voted 9-3 that available evidence does not support the efficacy of deramiocel for DMD-associated cardiomyopathy. A second heavy-volume decline followed.

Alleged Market Impact by the Numbers

• Class Period high: $35.34 per share on April 21, 2026
• July 27, 2026 close: $7.00, a one-day drop of $12.70 (64%)
• July 30, 2026 close: $4.19, a further drop of $2.38 (36%)
• Cumulative decline from Class Period high: $31.15 per share, or approximately 88%
• Both decline sessions occurred on unusually heavy trading volume
• The PDUFA target action date of August 22, 2026 had been publicly reaffirmed weeks earlier

What the Complaint Says Was Omitted

The action claims investors were not told that Capricor adopted changes to the pre-specified statistical analysis plan for HOPE-3, that the final SAP version 3.0 dated November 24, 2025 was never submitted to or agreed upon by FDA before the BLA resubmission, and that FDA therefore regarded the supporting analyses as “post-hoc and exploratory.” As alleged, this created substantial undisclosed risk to approval while shares traded at inflated prices.

“The size and speed of this repricing raise serious questions about whether investors had access to material information about how the HOPE-3 data were analyzed. The complaint alleges that key facts about the statistical analysis plan were not disclosed until FDA published its own assessment.” — Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the CAPR Lawsuit

Q: How much did CAPR stock drop? A: Shares fell approximately 78.7%, a decline of an aggregate $15.08 per share across two corrective disclosures, after FDA briefing documents disclosed unagreed changes to the pre-specified statistical analysis plan and an advisory committee voted 9-3 against supporting efficacy. Investors who purchased shares during the Class Period at artificially inflated prices and suffered losses may be eligible to seek compensation.

Q: When did Capricor Therapeutics, Inc. allegedly mislead investors? A: The Class Period runs from December 17, 2025 to July 26, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.

Q: What court was the CAPR class action filed in? A: The case was filed in the United States District Court for the Southern District of California, governed by the Private Securities Litigation Reform Act of 1995.

Q: What do CAPR investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my CAPR shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis. No upfront fees, no retainer, and no out-of-pocket costs. Any attorneys’ fees and expenses awarded to class counsel are subject to court approval.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected]\
Tel: (212) 363-7500\
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/capr-upcoming-deadline-levi–korsinsky-alerts-capricor-therapeutics-inc-stockholders-of-securities-class-action—contact-the-firm-302849631.html

SOURCE Levi & Korsinsky, LLP

Notice to Pension Funds, Asset Managers, and Fiduciaries: Hub Group’s $77 Million Cost Understatement and Subsequent Restatement of Three Years of Financial Results May Trigger Fiduciary Review Obligations for Institutional Holders

NEW YORK, Aug. 12, 2026 /PRNewswire/ — Institutional investors holding positions in Hub Group, Inc. (NASDAQ: HUBG) during the period from April 28, 2023, through May 11, 2026, may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

Hub Group shares fell from $51.33 on February 5, 2026, to $36.62 by May 12, 2026, a cumulative decline of approximately $14.71 per share (28.6%), across two corrective disclosures. The window to apply for lead plaintiff closes on August 28, 2026.

Notice to Institutional Holders

Pension funds, mutual funds, endowments, and asset managers that held HUBG during the class period face potential portfolio losses stemming from what the lawsuit describes as a multi-year pattern of misstated financials. The Company ultimately acknowledged that financial statements spanning 2023, 2024, and the first nine months of 2025 could no longer be relied upon. For institutions with fiduciary obligations, these disclosures may require affirmative evaluation of recovery options.

ERISA and Fiduciary Considerations

Fiduciaries overseeing portfolios that included HUBG securities have an obligation to assess whether pursuing recovery through the lead plaintiff process serves their beneficiaries’ interests. Serving as lead plaintiff provides direct oversight of litigation strategy and settlement negotiations, which can be particularly valuable for institutions with concentrated losses.

Fiduciary Obligations and Recovery Options

• Institutional holders with the largest documented losses are given priority for lead plaintiff appointment under the PSLRA
• Lead plaintiffs select and direct class counsel, influencing the trajectory and efficiency of the litigation
• Serving as lead plaintiff carries no additional financial risk; securities class actions proceed on a contingency basis with no out-of-pocket cost
• Fiduciaries who fail to evaluate lead plaintiff opportunities when losses are substantial may face questions about whether they fulfilled their duty to act in beneficiaries’ best interests
• Institutions need not have sold their positions to participate; losses are measured against the artificially inflated purchase prices paid during the class period
• Multiple corrective events across 2026 created staggered losses that may affect different portfolio entry points differently

Contact us for institutional recovery options or call (212) 363-7500.

“Institutional investors play a critical role in securities class actions. In the Hub Group matter, the Company’s admission that financial statements for 2023, 2024, and the first nine months of 2025 were unreliable creates a significant recovery opportunity that fiduciaries should evaluate carefully.” — Joseph E. Levi, Esq.

Case Summary

The securities action alleges Hub Group understated its largest operating expense, purchased transportation and warehousing costs, by an estimated $77 million in the first nine months of 2025 alone, while also prematurely or incorrectly recognizing revenue on certain transactions dating back to 2023. The Company’s officers repeatedly certified the effectiveness of internal controls during this period. Two corrective disclosures, on February 5, 2026, and May 12, 2026, revealed the scope of the misstatements and drove cumulative share price declines exceeding 28%.

Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the HUBG Lawsuit

Q: Who is eligible to join the HUBG investor lawsuit? A: Investors who purchased HUBG stock or securities between April 28, 2023, and May 11, 2026, and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What is the HUBG lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is August 28, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I already sold my HUBG shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: Can I join a different law firm’s lawsuit instead? A: Multiple firms often file competing complaints. The court consolidates and appoints a single lead counsel. Contacting Levi & Korsinsky before August 28, 2026, ensures your losses are considered.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of investor’s country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/hubg-shareholder-alert-hub-group-inc-securities-class-action-lawsuit—investors-with-losses-may-contact-levi–korsinsky-302849584.html

SOURCE Levi & Korsinsky, LLP

From IPO to implosion in six months: a chronological breakdown of how Megan Holdings Limited stock surged more than 400% on the back of a fraudulent pump-and-dump scheme before collapsing 93.4% in a single trading day.

NEW YORK, Aug. 12, 2026 /PRNewswire/ — Levi & Korsinsky, a national securities litigation firm, reminds investors that a class action complaint has been filed in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Megan Holdings Limited (NASDAQ: MGN) securities between September 26, 2025, and March 25, 2026, inclusive. The lawsuit also asserts claims on behalf of investors who purchased shares pursuant or traceable to the Company’s initial public offering.

Investors who suffered losses on their MGN investments are encouraged to obtain additional information and learn about participating in this action or contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

A Six-Month Timeline of AllegedFraud
The complaint filed against Megan Holdings and its officers paints a detailed chronological picture of how a purported Malaysian aquaculture company became the vehicle for a market manipulation and pump-and-dump scheme that ultimately destroyed over 93% of shareholder value in a single day. The following timeline, drawn from the allegations in the complaint, traces the key events from the Company’s IPO through its catastrophic stock collapse.

September 26, 2025 — The IPO
Megan Holdings Limited filed its IPO Prospectus, which formed part of the Registration Statement permitting the Company to issue 1,250,000 ordinary shares at an initial offering price of $4.00 per share, raising $5,000,000 in gross proceeds. D. Boral Capital LLC served as the sole bookrunning manager and underwriter on a firm commitment basis.

The Prospectus described Megan as “a company principally engaged in the development, construction and maintenance of aquaculture farms and related works” operating in Malaysia, with a focus on shrimp farm maintenance and the design of hatchery centers. Management outlined plans to allocate expected net proceeds of approximately US$2,801,000 across four areas: 20% for sales and marketing, 30% for expansion through mergers and acquisitions, 30% for development of a proprietary “Smart Farming System,” and 20% for working capital.

Critically, the complaint alleges the Prospectus contained materially false and misleading statements and omissions, including a failure to disclose that the Company was the subject of a market manipulation scheme, that its underwriter DBC had a troubling track record of conducting microcap IPOs that suffered similar manipulation-induced collapses, and that the Company suffered from material weaknesses in its internal accounting and financial reporting controls.

September 29, 2025 — IPO Completion
Megan Holdings completed its initial public offering and its ordinary shares began trading on the NASDAQ Capital Market under the ticker symbol “MGN.” Shares were sold at $4.00 per share.

September 2025 Through February 2026 — Class Period Trading
During these months, the complaint alleges, impersonators acting as financial advisors touted Megan Holdings stock in online forums, chat groups, and social media posts using baseless claims designed to create a buying frenzy among retail investors. The complaint asserts that these individuals used social-media based misinformation to build false narratives around the stock, laying the groundwork for the pump-and-dump scheme that would culminate in the spring.

During this period, the Company’s own risk factor disclosures acknowledged in boilerplate language that “[c]ertain recent initial public offerings of companies with public floats comparable to the anticipated public float of our company have experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company.” However, the complaint alleges these disclosures were materially inadequate because they failed to address the specific, realized risk that Megan’s own stock was being actively manipulated.

Meanwhile, the complaint alleges, the Company’s auditor, WWC, P.C., had issued a clean audit opinion on the financial statements incorporated into the Registration Statement despite the existence of material weaknesses in internal controls. WWC served as Megan’s auditor from 2022 through December 15, 2025.

February 25, 2026 — The Pump Begins in Earnest
Megan Holdings stock closed at $1.23 per share on February 25, 2026. Over the next four weeks, the stock would surge more than 400% despite the absence of any fundamental news, material corporate developments, or operational changes that could justify such a dramatic price increase. The complaint alleges this meteoric rise was the direct product of the coordinated promotional scheme.

March 25, 2026 — The Peak
MGN shares reached an intraday high of $5.18 per share — exceeding even the $4.00 IPO price — and closed at $4.24 per share. By this point, the stock had appreciated more than 320% from its February 25 closing price. The complaint alleges no legitimate business catalyst supported this valuation. The pump phase of the scheme was complete.

March 26, 2026 — The Dump: A 93.4% Single-Day Collapse
The fraudulent promotion scheme collapsed. Megan Holdings shares plummeted 93.4%, falling $3.96 from the prior day’s close of $4.24 to close at just $0.28 per share. The stock has not recovered and continues to trade well below that level.

The complaint alleges that the sudden collapse revealed the true nature of Megan’s trading activity — that the stock had been artificially inflated by a coordinated market manipulation scheme involving impersonators posing as financial professionals, and that once the promotional activity ceased, the stock returned to a level reflecting the Company’s actual value.

The Underwriter’s Track Record
The complaint further alleges that Megan’s IPO underwriter, D. Boral Capital LLC, had conducted numerous other microcap initial public offerings since January 2024 that followed a strikingly similar pattern of manipulation-induced volatility and collapse, including:

• Park Ha Biological Technology, Co. Ltd. (December 2024 IPO at $4.00/share) — collapsed in July 2025, losing 94% of its value;
• Masonglory Limited (July 2025 IPO) — collapsed approximately 97.6% from its highest closing price, including an 85.5% single-day decline on October 2, 2025;
• Phoenix Asia Holding (April 2025 IPO) — surged from $12.35 to $133.12 on January 30, 2026, then crashed to $17.60 the next trading day;
• Robot Consulting Co., Ltd. (July 2025 IPO) — trading halted by the SEC, with a subsequent NASDAQ halt that remains in effect;
• rYojbaba Co., Ltd. (August 2025 IPO) — experienced a dramatic run-up to $11.43 intraday before declining sharply, now trading at just $1.99.

The complaint alleges these patterns should have alerted all Defendants to the heightened risk that Megan’s IPO would be similarly exploited.

Legal Claims
The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, as well as Sections 11, 12(a)(2), and 15 of the Securities Act of 1933. The complaint names as defendants the Company; its CEO and Executive Director, Darren Hoo AKA Hoo Wei Sern; its CFO, Ng Kai Tie; its former auditor, WWC, P.C.; and its IPO underwriter, D. Boral Capital LLC.

Lead Plaintiff Deadline: September 8, 2026
If you suffered a loss on your investment in Megan Holdings Limited and wish to learn more about this class action, request additional information about participating in or leading this lawsuit now. You may also contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. The lead plaintiff deadline is September 8, 2026.

Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered. Attorney Advertising. Prior results do not guarantee similar outcomes.

Frequently Asked Questions About the MGN Lawsuit

Q: How much did MGN stock drop? A: Shares fell approximately 93.4% — a decline of $3.96 per share — after the collapse of the pump-and-dump promotional scheme on March 26, 2026. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.

Q: When did Megan Holdings Limited allegedly mislead investors? A: The class period runs from September 26, 2025, to March 25, 2026. The allegedfraud was revealed through corrective disclosures on March 26, 2026, when the market manipulation scheme collapsed and the stock price fell 93.4% in a single trading session.

Q: Who are the defendants named in the MGN lawsuit? A: The complaint names Megan Holdings Limited and individual defendants including CEO and Executive Director Darren Hoo AKA Hoo Wei Sern and CFO Ng Kai Tie, who signed SEC filings, made public statements, and bore responsibility for the accuracy of the Company’s disclosures. It also names the Company’s former auditor, WWC, P.C., and IPO underwriter, D. Boral Capital LLC.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my MGN shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/mgn-shareholder-alert-megan-holdings-limited-securities-class-action-lawsuit—investors-with-losses-may-contact-levi–korsinsky-302849240.html

SOURCE Levi & Korsinsky, LLP

Executive Accountability: Jeff Hernandez, Black Rock Coffee Bar’s Board Chairman, Signed the Registration Statement That Allegedly Concealed Store Cannibalization Risks from IPO Investors

NEW YORK, Aug. 12, 2026 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors that Jeff Hernandez, Chairman of the Board of Black Rock Coffee Bar, Inc. (NASDAQ: BRCB), is named as a defendant in a securities class action alleging the Company’s September 2025 IPO Registration Statement concealed material cannibalization risks from investors who purchased shares between September 12, 2025 and May 12, 2026. Find out if you qualify to recover your investment losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

BRCB shares have fallen more than 63% from the $20.00 IPO price, closing as low as $7.23 per share. On May 13, 2026 alone, shares dropped $3.32, or 30.3%, after the Company disclosed that new store openings were cannibalizing existing locations.

Jeff Hernandez’s Role During the Class Period

As Chairman of the Board, Hernandez signed or authorized the signing of the Registration Statement filed in connection with Black Rock Coffee’s September 2025 IPO. That Registration Statement represented the Company would “focus our growth in existing markets where we believe there is an opportunity to increase density with minimal sales transfer.” The complaint identifies Hernandez as bearing responsibility for the accuracy of these representations under Section 11 of the Securities Act.

What Hernandez Allegedly Oversaw

The action contends that as Board Chairman, Hernandez oversaw corporate governance during a period when:

• The Registration Statement claimed the Company’s expansion strategy was designed to achieve density with “minimal sales transfer”
• The IPO raised approximately $306.5 million from the sale of 16,911,764 Class A shares at $20.00 per share
• The Company opened 32 new stores in 2025 while targeting 20% average annual growth and 1,000 stores by 2035
• Same store sales growth decelerated from 10.8% in Q3 2025 to 5.2% in Q1 2026, a decline the CEO attributed to cannibalization creating a “160 basis point headwind to same-store sales” in Phoenix alone
• Investors were not told that the aggressive expansion strategy was already producing the very sales transfer the Registration Statement characterized as a future hypothetical

Hernandez’s Certifications and Section 11 Liability

Under Section 11 of the Securities Act, every person who signed a registration statement bears liability if that document contained untrue statements of material fact or omitted material facts necessary to make the statements not misleading. The complaint alleges Hernandez signed the Registration Statement that characterized store cannibalization as a risk that “may be significant in the future” when, as alleged, the dynamic was already affecting operations.

Section 15 of the Securities Act further imposes liability on persons who controlled the issuer at the time the Registration Statement became effective. As Board Chairman, Hernandez is alleged to have been a controlling person of Black Rock Coffee.

“Individual officers who sign SEC certifications bear personal responsibility for the accuracy of corporate disclosures. When a registration statement characterizes an active problem as a hypothetical future risk, every signatory is accountable to the investors who relied on that document,” stated Joseph E. Levi, Esq.

LEAD PLAINTIFF DEADLINE: August 17, 2026

Speak with an attorney about your potential recovery or call (212) 363-7500.

Levi & Korsinsky, LLP, Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered for investors.

Frequently Asked Questions About the BRCB Lawsuit

Q: Who are the defendants named in the BRCB lawsuit? A: The complaint names Black Rock Coffee Bar, Inc. and individual defendants including CEO Mark Davis, CFO Rodderick Booth, Board Chairman Jeff Hernandez, additional directors, and seven underwriter defendants including J.P. Morgan Securities, Jefferies, and Morgan Stanley.

Q: What is the BRCB lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is August 17, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: What if I already sold my BRCB shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What do BRCB investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-black-rock-coffee-bar-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-17-2026—brcb-302849603.html

SOURCE Levi & Korsinsky, LLP

Important Notice Regarding Alleged Market Manipulation and Short Squeeze Misrepresentations in Avis Budget Group Securities

NEW YORK, Aug. 12, 2026 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Avis Budget Group, Inc. (NASDAQ: CAR) that a class action has been filed on behalf of shareholders who purchased or otherwise acquired Avis securities between February 20, 2025 and April 21, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

CAR shares surged roughly 419% between April 1 and April 21, 2026, then collapsed 74.51%. Applications to serve as lead plaintiff must be filed by September 29, 2026.

The Alleged Pump-and-Dump Methodology

According to the lawsuit, Pentwater Capital Management LP accumulated a total economic interest of approximately 51% of Avis through common stock and cash-settled swaps by March 2026. The complaint alleges that this aggressive purchasing, combined with heavy existing short interest in CAR, triggered a short squeeze that drove the stock from under $200 per share to an intraday high of $765.94. The lawsuit contends that the resulting price action did not reflect Avis’s underlying business fundamentals, which included disappointing full-year 2025 results.

How the Alleged Scheme Affected Reported Market Prices

The complaint alleges that after the stock peaked, 4.3 million shares were sold into the market across April 22 and April 23, 2026, generating gross proceeds of $1.75 billion. The lawsuit contends that dumping that quantity of stock in two trading sessions caused CAR’s price to plunge, harming investors who purchased at allegedly manipulated prices. Claims are asserted under Sections 9(a) and 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5.

Key Manipulation Allegations for Shareholders

• The complaint alleges a series of transactions designed to raise CAR’s price for the purpose of inducing purchases by others.
• Purchases allegedly continued in the midst of a short-squeeze dynamic, forcing short sellers to cover at escalating prices.
• The lawsuit contends the accumulated stake reached 51% total economic interest through stock and cash-settled swaps.
• Approximately 4.3 million shares were allegedly liquidated over two sessions for $1.75 billion in proceeds.
• The action alleges the scheme was structured in a way that made the conduct difficult for ordinary market participants to detect.
• Investors who bought CAR common stock to cover short positions during the Class Period are included in the proposed class.

“This case presents important questions about market manipulation and disclosure obligations when a single holder allegedly amasses a 51% economic interest in a widely shorted stock. The allegations concerning the sale of 4.3 million shares over two trading sessions warrant close scrutiny on behalf of investors.” — Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the CAR Lawsuit

Q: What is the CAR class action lawsuit about? A: A securities class action has been filed alleging that Pentwater Capital Management LP and its CEO engaged in a scheme that artificially inflated the market price of Avis Budget Group, Inc. (NASDAQ: CAR) securities between February 20, 2025 and April 21, 2026. Pentwater then sold a significant portion of its CAR ownership, allegedly reaping the benefit of the inflated stock price while sending the stock tumbling nearly 75%.

Q: Who is eligible to join the CAR investor lawsuit? A: Investors who purchased or acquired CAR stock or securities between February 20, 2025 and April 21, 2026 and suffered financial losses may be eligible, including those who bought common stock to cover a short position. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did CAR stock drop? A: Shares reached a peak closing price of $713.97 on April 21, 2026. The following day, the stock fell approximately 37.82%, or $270.03, to close at $443.94. Shares slid a further approximate $261.94, closing at only $182.005 on April 28, 2026. Investors who purchased during the Class Period at allegedly inflated prices may be eligible to seek compensation.

Q: What court was the CAR class action filed in? A: The case was filed in the United States District Court for the Middle District of Florida.

Q: What do CAR investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my CAR shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis, with no retainer and no out-of-pocket costs. Any attorneys’ fees and expenses awarded to class counsel are subject to court approval.

CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected]\
Tel: (212) 363-7500\
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/car-upcoming-deadline-levi–korsinsky-alerts-pentwater-capital-management-lp-stockholders-of-securities-class-action—contact-the-firm-302849613.html

SOURCE Levi & Korsinsky, LLP

A securities class action alleges iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) warned only in generic terms about microcap volatility while omitting the specific, realized risk of a coordinated manipulation scheme, and that iTonic shareholders lost roughly $30.35 per share when the stock collapsed.

NEW YORK, Aug. 12, 2026 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) (NASDAQ: ITOC, PTHL) that a securities class action has been filed on behalf of shareholders who purchased securities between September 5, 2024 and July 29, 2025. Submit your information. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

iTonic shares fell from an intraday high of $32.00 on July 28, 2025 to close at approximately $1.65 on July 29, 2025, a decline of nearly 95%. Lead plaintiff applications must be submitted by September 29, 2026.

What the Company Disclosed

SEC filings stated that “there have been instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with a number of recent initial public offerings, especially among companies with relatively smaller public floats.” The offering documents also identified two material weaknesses in internal control over financial reporting, described as a lack of sufficient personnel with appropriate levels of accounting knowledge and a lack of formal policies and procedures to establish risk assessment processes and an internal control framework.

What Plaintiffs Allege Was Missing

The complaint challenges the adequacy of those warnings, contending that the disclosures never identified the specific risk that ultimately materialized. The action alleges that the offering documents omitted that the securities were exposed to a coordinated promotional and manipulation scheme, and that the auditor and underwriters engaged for the $9,000,000 September 2024 offering at $4.00 per share had been associated with other foreign microcap listings that later experienced structurally similar collapses.

Disclosure Gaps Alleged

• Risk factor language addressed volatility generally but allegedly did not warn of promotional manipulation targeting the specific security
• No disclosure allegedly addressed the professional histories of the offering participants in comparable foreign microcap listings
• Internal control material weaknesses were disclosed as boilerplate without alleged connection to oversight of trading and disclosure risk
• The lawsuit contends fabricated rumors of a Gilead Sciences transaction circulated without timely corrective disclosure
• The Company later stated that its share price had been “influenced” by “false rumors” and that it had “no contact with Gilead”
• Plaintiffs allege the surge to $32.00 occurred without any material corporate development supporting the valuation

“Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company’s operations. The complaint alleges iTonic filings warned about microcap volatility in the abstract while omitting the manipulation risk that plaintiffs say actually materialized.” — Joseph E. Levi, Esq.

Act now. Click here to learn more or call (212) 363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the iTonic Lawsuit

Q: What specific misstatements does the iTonic lawsuit allege? A: The complaint alleges iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) made materially false or misleading statements and omissions regarding the risk of market manipulation affecting its shares, the histories of its auditor and underwriters with similar foreign microcap offerings, and its internal controls. When the artificial nature of the price surge was exposed on July 29, 2025, the stock declined sharply.

Q: What court was the iTonic class action filed in? A: The case was filed in the United States District Court for the Southern District of New York, governed by the Private Securities Litigation Reform Act of 1995.

Q: Who are the defendants named in the iTonic lawsuit? A: The complaint names the Company and individual defendants including senior executives who signed SEC filings and certified financial disclosures, along with the offering’s auditor and underwriters.

Q: What do iTonic investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my iTonic shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis, with no retainer and no out-of-pocket costs. Any attorneys’ fees and expenses awarded to class counsel are subject to court approval.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected]\
Tel: (212) 363-7500\
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/itoc-pthl-upcoming-deadline-levi–korsinsky-alerts-itonic-holdings-ltd-fka-pheton-holdings-ltd-stockholders-of-securities-class-action—contact-the-firm-302849623.html

SOURCE Levi & Korsinsky, LLP